Furthermore, if the residual BTD enzyme activity in an individual changed to 30% or more (ascertained in two independent analyses), the biotin supplementation was stopped, and the individual was no longer treated for BTD deficiency. The gene discussed is BTD; the disease is biotinidase deficiency.